Zachary Hale, APRN
Primary Care · Beavercreek, OHNPI 1356992028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 437 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,685, 3.1 times the $865 reported in 2022. Among primary care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 437 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Lilly USA, LLC$954
- Novo Nordisk$663
- Exact Sciences$557
- Pfizer$510
- plus $2K from 21 others
What the payments were for
- Food & beverage$7,073100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $1,403 |
| AstraZeneca | 39 | $1,010 |
| Lilly USA, LLC | 55 | $954 |
| Novo Nordisk | 48 | $663 |
| Exact Sciences | 22 | $557 |
| Pfizer | 35 | $510 |
| Boehringer Ingelheim | 35 | $496 |
| Merck | 16 | $271 |
| GSK | 20 | $233 |
| Astellas Pharma US Inc | 8 | $188 |
| Amgen | 8 | $135 |
| Abbott | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $61 |
| Novartis | 3 | $54 |
| Bayer | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Renalytix AI, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Seqirus USA Inc | 2 | $30 |
| Radius Health, Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Lundbeck LLC | 1 | $20 |
| Gilead | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,073 in reported general payments places this provider in the 95th percentile of 321 primary care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 51 | $51,738 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $22,666 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $17,052 |
| LinzessLinaclotide | 14 | $10,397 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $2,017 |
| Pregabalin | 15 | $950 |
| Atorvastatin Calcium | 94 | $812 |
| Gabapentin | 31 | $812 |
| SynthroidLevothyroxine Sodium | 20 | $783 |
| Levothyroxine Sodium | 52 | $596 |
| Omeprazole | 61 | $574 |
| Bupropion XlBupropion Hcl | 21 | $554 |
| Sucralfate | 11 | $502 |
| Pantoprazole Sodium | 27 | $494 |
| Losartan Potassium | 59 | $408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $496 | $51,73851 claims |
| AstraZenecaBreztri Aerosphere | $1,010 | $22,66636 claims |
| GSKTrelegy Ellipta | $233 | $17,05213 claims |
| AbbVieLinzess, Synthroid | $1,403 | $11,18034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 321 primary care providers in Ohio.
Other primary care in Beavercreek
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
- Lindsay ChappellFairlawn$11K
- Laura HolligerNorth Canton$10K
- Caitlyn FrantzDayton$10K
- Brandy RichardsCleveland$8K
- Regan HeagenFindlay$8K
- Katherine ElliotWesterville$7K
- Stephanie EmmettMayfield Heights$7K
- Joseph PriceColumbus$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.